AR101077A1 - Triterpenoides con actividad inhibidora de la maduración de hiv - Google Patents
Triterpenoides con actividad inhibidora de la maduración de hivInfo
- Publication number
- AR101077A1 AR101077A1 ARP150101078A ARP150101078A AR101077A1 AR 101077 A1 AR101077 A1 AR 101077A1 AR P150101078 A ARP150101078 A AR P150101078A AR P150101078 A ARP150101078 A AR P150101078A AR 101077 A1 AR101077 A1 AR 101077A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- group
- cycloalkyl
- coor2
- Prior art date
Links
- 230000035800 maturation Effects 0.000 title abstract 2
- 150000003648 triterpenes Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 24
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- -1 -fluoroalkyl C1−6 Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos que tienen propiedades que afectan los fármacos y biopropiedades, sus composiciones farmacéuticas y métodos de uso. En particular, se proporcionan triterpenoides que poseen actividad antiviral exclusiva como inhibidores de la maduración de HIV. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), incluyendo sus sales farmacéuticamente aceptables, en donde R¹ es isopropenilo o isopropilo; X está seleccionado del grupo de cicloalquilo C₄₋₈, cicloalquenilo C₄₋₈, espirocicloalquilo C₄₋₉, espirocicloalquenilo C₄₋₉, oxacicloalquilo C₄₋₈, dioxacicloalquilo C₄₋₈, oxacicloalquenilo C₆₋₈, dioxacicloalquenilo C₆₋₈, ciclodialquenilo C₆, oxaciclodialquenilo C₆, oxaespirocicloalquilo C₆₋₉ y anillo oxaespirocicloalquenilo C₆₋₉, en donde X está sustituido con A y en donde A es -alquil C₁₋₆-halo; Y está seleccionado del grupo de -COOR², -C(O)NR²SO₂R³, -C(O)NHSO₂NR²R², -NR²SO₂R², -SO₂NR²R², -cicloalquil C₃₋₆-COOR², -alquenil C₂₋₆-COOR², -alquinil C₂₋₆-COOR², -alquil C₁₋₆-COOR², -alquilo C₁₋₆ sustituido con alquilo, -CF₂-COOR², -NHC(O)(CH₂)ₙ-COOR², -SO₂NR²C(O)R², -tetrazol y -CONHOH, en donde n = 1 - 6; R² es -H, -alquilo C₁₋₆, -alquilo C₁₋₆ sustituido con alquilo o -alquilo C₁₋₆ sustituido con arilo; W está ausente o es -CH₂ o -CO; R³ es -H, -alquilo C₁₋₆ o -alquilo C₁₋₆ sustituido con alquilo; R⁴ está seleccionado del grupo de -H, -alquilo C₁₋₆, -alquil C₁₋₆-cicloalquilo C₃₋₆, -alquilo C₁₋₆ sustituido en C₁₋₆, -alquil C₁₋₆-Q¹, -alquil C₁₋₆-cicloalquil C₃₋₆-Q¹, arilo, heteroarilo, heteroarilo sustituido, -COR⁶, -SO₂R⁷, -SO₂NR²R² y un resto de fórmula (2) o (3), en donde G está seleccionado del grupo de -O-, -SO₂- y -NR¹²; en donde Q¹ está seleccionado del grupo de -alquilo C₁₋₆, -fluoroalquilo C₁₋₆, heteroarilo, heteroarilo sustituido, halógeno, -CF₃, -OR², -COOR², -NR⁸R⁹, -CONR⁸R⁹ y -SO₂R⁷; R⁵ está seleccionado del grupo de -H, -alquilo C₁₋₆, -cicloalquilo C₃₋₆, -alquilo sustituido con alquilo C₁₋₆, -alquil C₁₋₆-NR⁸R⁹, -COR³, -SO₂R⁷ y -SO₂NR²R²; siempre que R⁴ o R⁵ no puedan ser -COR⁶ cuando W es -CO; también siempre que sólo uno de R⁴ o R⁵ pueda estar seleccionado del grupo de -COR⁶, -COCOR⁶, -SO₂-R⁷ y -SO₂NR²R²; o cuando W está ausente o es -CH₂, entonces R⁴ y R⁵ se pueden tomar junto con el N adyacente para formar un resto de fórmula (4); R⁶ está seleccionado del grupo de -H, -alquilo C₁₋₆, -alquilo C₁₋₆ sustituido con alquilo, -cicloalquilo C₃₋₆, -cicloalquil C₃₋₆ sustituido-Q², -alquil C₁₋₆-Q², -alquil C₁₋₆ sustituido con alquil-Q², -cicloalquil C₃₋₆-Q², aril-Q², -NR¹³R¹⁴ y -OR¹⁵; en donde Q² está seleccionado del grupo de arilo, heteroarilo, heteroarilo sustituido, -OR², -COOR², -NR⁸R⁹, SO₂R⁷, -CONHSO₂R³ y -CONHSO₂NR²R²; R⁷ está seleccionado del grupo de -H, -alquilo C₁₋₆, -alquilo sustituido en C₁₋₆, -cicloalquilo C₃₋₆, -CF₃, arilo y heteroarilo; R⁸ y R⁹ están seleccionados, de modo independiente, del grupo de -H, -alquilo C₁₋₆, -alquilo sustituido en C₁₋₆, arilo, heteroarilo, arilo sustituido, heteroarilo sustituido, -alquil C₁₋₆-Q² y -COOR³, o R⁸ y R⁹ se toman junto con el N adyacente para formar un ciclo seleccionado del grupo de fórmulas (5); M está seleccionado del grupo de -R¹⁵, -SO₂R², -SO₂NR²R², -OH y -NR²R¹²; V está seleccionado del grupo de -CR¹⁰R¹¹-, -SO₂-, -O- y -NR¹²-; siempre que sólo uno de R⁸ o R⁹ pueda ser -COOR³; R¹⁰ y R¹¹ están seleccionados, de modo independiente, del grupo de -H, -alquilo C₁₋₆, -alquilo C₁₋₆ sustituido y -cicloalquilo C₃₋₆; R¹² está seleccionado del grupo de -H, -alquilo C₁₋₆, -alquilo C₁₋₆ sustituido con alquilo, -CONR²R², -SO₂R³, -SO₂NR²R²; R¹³ y R¹⁴ están seleccionados, de modo independiente, del grupo de -H, -alquilo C₁₋₆, -cicloalquilo C₃₋₆, -alquilo sustituido en C₁₋₆, -alquil C₁₋₆-Q³, -alquil C₁₋₆-cicloalquil C₁₋₆-Q³, alquil sustituido en C₁₋₆-Q³ y un resto de fórmula (6); Q³ está seleccionado del grupo de heteroarilo, heteroarilo sustituido, -NR²R¹², -CONR²R², -COOR², -OR² y -SO₂R³; R¹⁵ está seleccionado del grupo de -alquilo C₁₋₆, -cicloalquilo C₃₋₆, -alquilo sustituido en C₁₋₆, -alquil C₁₋₆-Q³, -alquil C₁₋₆-cicloalquil C₃₋₆-Q³ y -alquil sustituido en C₁₋₆-Q³; R¹⁶ está seleccionado del grupo de -H, -alquilo C₁₋₆, -NR²R² y -COOR²; siempre que, cuando V es -NR¹²-; R¹⁶ no pueda ser -NR²R²; y R¹⁷ está seleccionado del grupo de -H, -alquilo C₁₋₆, -COOR³ y arilo. Reivindicación 18: Un compuesto intermediario caracterizado porque está seleccionado del grupo de fórmulas (7).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978306P | 2014-04-11 | 2014-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101077A1 true AR101077A1 (es) | 2016-11-23 |
Family
ID=53002809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101078A AR101077A1 (es) | 2014-04-11 | 2015-04-09 | Triterpenoides con actividad inhibidora de la maduración de hiv |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9527882B2 (es) |
| EP (2) | EP3129392B1 (es) |
| JP (1) | JP6568202B2 (es) |
| KR (1) | KR102411082B1 (es) |
| CN (1) | CN106604909B (es) |
| AR (1) | AR101077A1 (es) |
| AU (1) | AU2015243500B2 (es) |
| BR (1) | BR112016023414B1 (es) |
| CA (1) | CA2944778C (es) |
| CL (1) | CL2016002528A1 (es) |
| CR (1) | CR20160472A (es) |
| CY (1) | CY1123742T1 (es) |
| DK (1) | DK3129392T3 (es) |
| DO (1) | DOP2016000277A (es) |
| EA (1) | EA030178B1 (es) |
| ES (1) | ES2828705T3 (es) |
| HR (1) | HRP20201645T1 (es) |
| HU (1) | HUE051719T2 (es) |
| IL (1) | IL248053B (es) |
| LT (1) | LT3129392T (es) |
| MA (1) | MA39374A1 (es) |
| MX (1) | MX2016013425A (es) |
| NZ (1) | NZ724644A (es) |
| PE (1) | PE20161391A1 (es) |
| PH (1) | PH12016501951B1 (es) |
| PL (1) | PL3129392T3 (es) |
| PT (1) | PT3129392T (es) |
| RS (1) | RS60959B1 (es) |
| SG (2) | SG11201608041QA (es) |
| SI (1) | SI3129392T1 (es) |
| SM (1) | SMT202000581T1 (es) |
| TW (1) | TWI659964B (es) |
| UA (1) | UA120927C2 (es) |
| UY (1) | UY36070A (es) |
| WO (1) | WO2015157483A1 (es) |
| ZA (1) | ZA201606748B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36070A (es) | 2014-04-11 | 2015-10-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Triterpenoides con actividad inhibidora de la maduración de hiv |
| RU2018116772A (ru) * | 2015-11-20 | 2019-12-20 | ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД | Композиции ингибитора созревания ВИЧ |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| JP2019528304A (ja) * | 2016-08-31 | 2019-10-10 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及び治療 |
| PT3784349T (pt) * | 2018-04-24 | 2024-01-22 | Viiv Healthcare Uk No 5 Ltd | Compostos com atividade inibidora de maturação do hiv |
| SI3894424T1 (sl) | 2018-12-10 | 2023-04-28 | Viiv Healthcare Uk (No. 4) Limited | Mezilatna sol amino-lupanske spojine z zaviralno aktivnostjo dozorevanja HIV-a |
| CN109705189B (zh) * | 2018-12-29 | 2020-06-05 | 中国医学科学院药用植物研究所 | 具有式i所示结构的三萜衍生物及其制备方法和应用 |
| CN110981765A (zh) * | 2019-11-07 | 2020-04-10 | 肇庆巨元生化有限公司 | 一种25-羟基维生素d3中间体的制备方法 |
| US20230045509A1 (en) * | 2019-12-09 | 2023-02-09 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4906661A (en) | 1981-11-12 | 1990-03-06 | E. I. Du Pont De Nemours And Company | Esters of aryloxypropanolamine derivatives |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| AR035311A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| CA2560266A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US20090105203A1 (en) | 2006-10-16 | 2009-04-23 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| US20090062243A1 (en) * | 2007-08-03 | 2009-03-05 | Advanced Life Sciences, Inc. | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof |
| CA2714049A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17.beta. lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| WO2011153315A1 (en) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| PT2576586E (pt) | 2010-06-04 | 2015-10-23 | Bristol Myers Squibb Co | Amidas c-28 de derivados de ácido betulínico c-3 modificadas como inibidores de maturação de hiv |
| SG192144A1 (en) | 2011-01-31 | 2013-08-30 | Bristol Myers Squibb Co | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| ES2552512T3 (es) | 2011-01-31 | 2015-11-30 | Bristol-Myers Squibb Company | Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| UY36070A (es) | 2014-04-11 | 2015-10-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Triterpenoides con actividad inhibidora de la maduración de hiv |
-
2015
- 2015-04-09 UY UY0001036070A patent/UY36070A/es not_active Application Discontinuation
- 2015-04-09 PE PE2016001948A patent/PE20161391A1/es unknown
- 2015-04-09 EA EA201691760A patent/EA030178B1/ru unknown
- 2015-04-09 PT PT157184029T patent/PT3129392T/pt unknown
- 2015-04-09 BR BR112016023414-6A patent/BR112016023414B1/pt active IP Right Grant
- 2015-04-09 HU HUE15718402A patent/HUE051719T2/hu unknown
- 2015-04-09 UA UAA201609970A patent/UA120927C2/uk unknown
- 2015-04-09 JP JP2017504607A patent/JP6568202B2/ja active Active
- 2015-04-09 EP EP15718402.9A patent/EP3129392B1/en active Active
- 2015-04-09 LT LTEP15718402.9T patent/LT3129392T/lt unknown
- 2015-04-09 SI SI201531396T patent/SI3129392T1/sl unknown
- 2015-04-09 CN CN201580031487.2A patent/CN106604909B/zh active Active
- 2015-04-09 DK DK15718402.9T patent/DK3129392T3/da active
- 2015-04-09 NZ NZ724644A patent/NZ724644A/en unknown
- 2015-04-09 CA CA2944778A patent/CA2944778C/en active Active
- 2015-04-09 US US14/682,179 patent/US9527882B2/en active Active
- 2015-04-09 SM SM20200581T patent/SMT202000581T1/it unknown
- 2015-04-09 MX MX2016013425A patent/MX2016013425A/es active IP Right Grant
- 2015-04-09 CR CR20160472A patent/CR20160472A/es unknown
- 2015-04-09 RS RS20201276A patent/RS60959B1/sr unknown
- 2015-04-09 EP EP20187878.2A patent/EP3750910A1/en not_active Withdrawn
- 2015-04-09 TW TW104111466A patent/TWI659964B/zh active
- 2015-04-09 PL PL15718402T patent/PL3129392T3/pl unknown
- 2015-04-09 AR ARP150101078A patent/AR101077A1/es unknown
- 2015-04-09 SG SG11201608041QA patent/SG11201608041QA/en unknown
- 2015-04-09 AU AU2015243500A patent/AU2015243500B2/en active Active
- 2015-04-09 WO PCT/US2015/025029 patent/WO2015157483A1/en active Application Filing
- 2015-04-09 KR KR1020167031312A patent/KR102411082B1/ko active IP Right Grant
- 2015-04-09 SG SG10201709017PA patent/SG10201709017PA/en unknown
- 2015-04-09 ES ES15718402T patent/ES2828705T3/es active Active
- 2015-04-09 MA MA39374A patent/MA39374A1/fr unknown
-
2016
- 2016-09-26 IL IL248053A patent/IL248053B/en active IP Right Grant
- 2016-09-29 ZA ZA2016/06748A patent/ZA201606748B/en unknown
- 2016-10-03 PH PH12016501951A patent/PH12016501951B1/en unknown
- 2016-10-05 CL CL2016002528A patent/CL2016002528A1/es unknown
- 2016-10-11 DO DO2016000277A patent/DOP2016000277A/es unknown
- 2016-11-07 US US15/344,756 patent/US20170056420A1/en not_active Abandoned
-
2017
- 2017-08-16 US US15/678,381 patent/US10245275B2/en active Active
-
2019
- 2019-01-22 US US16/253,393 patent/US10780102B2/en active Active
-
2020
- 2020-08-03 US US16/983,052 patent/US11464790B2/en active Active
- 2020-10-13 HR HRP20201645TT patent/HRP20201645T1/hr unknown
- 2020-10-27 CY CY20201101017T patent/CY1123742T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| CR20120418A (es) | Inhibidores de virus flaviviridae | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| CR20180578A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| PE20151448A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| AR089285A1 (es) | Derivados de betulina | |
| AR089996A1 (es) | Triterpenoides de c-3 cicloalquenilo con actividad inhibidora de la maduracion del hiv | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR104879A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| AR094550A1 (es) | Inhibidores de btk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |